A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Data collected among patients with myelofibrosis after six months of ruxolitinib treatment aided researchers in developing the Response to Ruxolitinib after 6 months (RR6) prognostic model, which includes three risk categories: low (median OS not reached), intermediate (median OS 61 months, 95% CI 43-80), and high (median OS 33 months, 95% CI 21-50), and enables early identification of MF patients receiving ruxolitinib who many benefit from a treatment change.